A Randomized Study to Evaluate Antibody Response to an Additional Dose of SARS-CoV-2 Vaccination With and Without Immunosuppression Reduction in Kidney and Liver Transplant Recipients
Latest Information Update: 03 Apr 2024
Price :
$35 *
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms CPAT-ISR
- 28 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2023 Planned End Date changed from 1 Sep 2023 to 4 Mar 2025.
- 20 Sep 2023 Planned primary completion date changed from 1 Sep 2022 to 4 Mar 2024.